Letter: First-line monotherapies for chronic hepatitis B - Indirect comparison between entecavir and tenofovir

Alimentary Pharmacology and Therapeutics

Volumn 37, Issue 5, 2013, Pages 584-585

  Maratea, D ^a   Fadda, V ^a   Trippoli, S ^a   Messori, A ^a  

^a ESTAV Toscana Centro   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ADEFOVIR; ENTECAVIR; LAMIVUDINE; NUCLEOSIDE DERIVATIVE; TELBIVUDINE; TENOFOVIR;

DRUG EFFICACY; HEPATITIS B; HUMAN; LETTER; META ANALYSIS (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); TREATMENT RESPONSE;

ADENINE; ANTIVIRAL AGENTS; GUANINE; HEPATITIS B, CHRONIC; HUMANS; ORGANOPHOSPHONATES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; REVERSE TRANSCRIPTASE INHIBITORS; TREATMENT OUTCOME;

EID: 84873392960     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/apt.12212     Document Type: Letter

References (6)

1. European Association For The Study Of The Liver. EASL Clinical Practice Guidelines: management of chronic hepatitis B. J Hepatol 2009; 50: 227-42.
2. Lok AS, McMahon BJ,. Chronic hepatitis B: update 2009. Hepatology 2009; 50: 661-2.
3. Messori A, Del Santo F, Maratea D, Trippoli S,. Single-drug treatments for chronic hepatitis B: summarising current information by network meta-analysis. Aliment Pharmacol Ther 2011; 34: 105-7.
4. Messori A, Del Santo F, Maratea D,. First-line treatments for hepatitis C. Aliment Pharmacol Ther 2011; 33: 1383-5.
5. Woo G, Tomlinson G, Nishikawa Y, Kowgier M, Sherman M, et al,. Tenofovir and entecavir are the most effective antiviral agents for chronic hepatitis B: a systematic review and Bayesian meta-analyses. Gastroenterology 2010; 139: 1218-29.
6. Fadda V, Maratea D, Trippoli S, Messori A,. Network meta-analysis. Results can be summarised in a simple figure. BMJ 2011; 342: d1555.